Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America

Scott A Harper, John S Bradley, Janet A Englund, Thomas M File, Stefan Gravenstein, Frederick G Hayden, Allison J McGeer, Kathleen M Neuzil, Andrew T Pavia, Michael L Tapper, Timothy M Uyeki, Richard K Zimmerman, Expert Panel of the Infectious Diseases Society of America, Scott A Harper, John S Bradley, Janet A Englund, Thomas M File, Stefan Gravenstein, Frederick G Hayden, Allison J McGeer, Kathleen M Neuzil, Andrew T Pavia, Michael L Tapper, Timothy M Uyeki, Richard K Zimmerman, Scott A Harper, John S Bradley, Janet A Englund, Thomas M File, Stefan Gravenstein, Frederick G Hayden, Allison J McGeer, Kathleen M Neuzil, Andrew T Pavia, Michael L Tapper, Timothy M Uyeki, Richard K Zimmerman, Expert Panel of the Infectious Diseases Society of America, Scott A Harper, John S Bradley, Janet A Englund, Thomas M File, Stefan Gravenstein, Frederick G Hayden, Allison J McGeer, Kathleen M Neuzil, Andrew T Pavia, Michael L Tapper, Timothy M Uyeki, Richard K Zimmerman

Abstract

Guidelines for the treatment of persons with influenza virus infection were prepared by an Expert Panel of the Infectious Diseases Society of America. The evidence-based guidelines encompass diagnostic issues, treatment and chemoprophylaxis with antiviral medications, and issues related to institutional outbreak management for seasonal (interpandemic) influenza. They are intended for use by physicians in all medical specialties with direct patient care, because influenza virus infection is common in communities during influenza season and may be encountered by practitioners caring for a wide variety of patients.

Figures

Tabla 1.
Tabla 1.
Sistema de clasificación de la Sociedad de Enfermedades Infecciosas y del Servicio de Salud Pública de Estados Unidos de América para las recomendaciones en las guias de prácticas clinicas.
Tabla 2.
Tabla 2.
Personas que es necesario evaluar para detectar influenza
Tabla 3.
Tabla 3.
Personas con riesgo alto de complicaciones de influenza a quienes es posible tratar con antivirales.
Tabla 4.
Tabla 4.
Métodos de detección de la influenza
Tabla 5.
Tabla 5.
Interpretación de los resultados de pruebas de detección rápida de antigenos de influenza para muestras obtenidas de pacientes con enfermedad seudoinfluenza.
Tabla 6.
Tabla 6.
Dosis recomendadas para la medicación de antivirales para la influenza

References

    1. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA. 2004;292:1333–40.
    1. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179–86.
    1. Antiviral therapy and prophylaxis for influenza in children. Pediatrics. 2007;119:852–60.
    1. Bocchini JA, Jr, Bradley JS, Brady MT, et al. American Academy of Pediatrics Committee on Infectious Diseases. Prevention of influenza: recommendations for influenza immunization of children, 2008–2009. Pediatrics. 2008;122:1135–41.
    1. Fiore AE, Shay DK, Broder K, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep. 2008;57((RR-7)):1–60.
    1. Canadian Task Force on the Periodic Health Examination. The periodic health examination. CMAJ. 1979;121:1193–254.
    1. World Health Organization. Clinical management of human infection with avian influenza A (H5N1) virus. 15 August 2007. [Accessed 4 March 2009.]; Available at: .
    1. Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med. 2008;358:261–73.
    1. Hall CB, Dolin R, Gala CL, et al. Children with influenza A infection: treatment with rimantadine. Pediatrics. 1987;80:275–82.
    1. Palese P, Shaw M. Orthomyxoviridae: the viruses and their replication. In: Knipe DM, Howley PM, editors. Fields virology. 5th ed. Vol. 2. Lippincott: Williams & Wilkins; 2007. pp. 1647–90.
    1. Matsuzaki Y, Katsushima N, Nagai Y, et al. Clinical features of influenza C virus infection in children. J Infect Dis. 2006;193:1229–35.
    1. Lee PY, Matchar DB, Clements DA, Huber J, Hamilton JD, Peterson ED. Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. Ann Intern Med. 2002;137:225–31.
    1. Sullivan KM, Monto AS, Longini IM., Jr Estimates of the US health impact of influenza. Am J Public Health. 1993;83:1712–6.
    1. Evans CT, Lavela SL, Smith B, Miskevics S, Weaver FM, Goldstein B. Influenza diagnosis and treatment in veterans with spinal cord injury. Arch Phys Med Rehabil. 2006;87:291–3.
    1. Linder JA, Bates DW, Platt R. Antivirals and antibiotics for influenza in the United States, 1995–2002. Pharmacoepidemiol Drug Saf. 2005;14:531–6.
    1. Rothberg MB, Bonner AB, Rajab MH, Kim HS, Stechenberg BW, Rose DN. Effects of local variation, specialty, and beliefs on antiviral prescribing for influenza. Clin Infect Dis. 2006;42:95–9.
    1. Abanses JC, Dowd MD, Simon SD, Sharma V. Impact of rapid influenza testing at triage on management of febrile infants and young children. Pediatr Emerg Care. 2006;22:145–9.
    1. Blitz SG, Cram P, Chernew ME, Monto AS, Fendrick AM. Diagnostic testing or empirical neuraminidase inhibitor therapy for patients with influenza-like illness: what a difference a day makes. Am J Manag Care. 2002;8:221–7.
    1. Bonner AB, Monroe KW, Talley LI, Klasner AE, Kimberlin DW. Impact of the rapid diagnosis of influenza on physician decision-making and patient management in the pediatric emergency department: results of a randomized, prospective, controlled trial. Pediatrics. 2003;112:363–7.
    1. D'Heilly SJ, Janoff EN, Nichol P, Nichol KL. Rapid diagnosis of influenza infection in older adults: influence on clinical care in a routine clinical setting. J Clin Virol. 2008;42:124–8.
    1. Falsey AR, Murata Y, Walsh EE. Impact of rapid diagnosis on management of adults hospitalized with influenza. Arch Intern Med. 2007;167:354–60.
    1. Poehling KA, Zhu Y, Tang YW, Edwards K. Accuracy and impact of a point-of-care rapid influenza test in young children with respiratory illnesses. Arch Pediatr Adolesc Med. 2006;160:713–8.
    1. Sharma V, Dowd MD, Slaughter AJ, Simon SD. Effect of rapid diagnosis of influenza virus type A on the emergency department management of febrile infants and toddlers. Arch Pediatr Adolesc Med. 2002;156:41–3.
    1. Halloran ME, Piedra PA, Longini IM, Jr, et al. Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003–2004. Vaccine. 2007;25:4038–45.
    1. Piedra PA, Gaglani MJ, Kozinetz CA, et al. Trivalent live attenuated intranasal influenza vaccine administered during the 2003–2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Pediatrics. 2007;120:e553–64.
    1. Whitaker-Dowling P, Maassab HF, Youngner JS. Dominant-negative mutants as antiviral agents: simultaneous infection with the cold-adapted live-virus vaccine for influenza A protects ferrets from disease produced by wild-type influenza A. J Infect Dis. 1991;164:1200–2.
    1. Boivin G, Hardy I, Tellier G, Maziade J. Predicting influenza infections during epidemics with use of a clinical case definition. Clin Infect Dis. 2000;31:1166–9.
    1. Call SA, Vollenweider MA, Hornung CA, Simel DL, McKinney WP. Does this patient have influenza? JAMA. 2005;293:987–97.
    1. Monto AS, Gravenstein S, Elliott M, Colopy M, Schweinle J. Clinical signs and symptoms predicting influenza infection. Arch Intern Med. 2000;160:3243–7.
    1. Quach C, Piche-Walker L, Platt R, Moore D. Risk factors associated with severe influenza infections in childhood: implication for vaccine strategy. Pediatrics. 2003;112:e197–201.
    1. Rojo JC, Ruiz-Contreras J, Fernandez MB, Marin MA, Folgueira L. Influenza-related hospitalizations in children younger than three years of age. Pediatr Infect Dis J. 2006;25:596–601.
    1. Wang YH, Huang YC, Chang LY, et al. Clinical characteristics of children with influenza A virus infection requiring hospitalization. J Microbiol Immunol Infect. 2003;36:111–6.
    1. Wootton SH, Scheifele DW, Mak A, Petric M, Skowronski DM. Detection of human influenza virus in the stool of children. Pediatr Infect Dis J. 2006;25:1194–5.
    1. Meury S, Zeller S, Heininger U. Comparison of clinical characteristics of influenza and respiratory syncytial virus infection in hospitalised children and adolescents. Eur J Pediatr. 2004;163:359–63.
    1. Guarner J, Paddock CD, Shieh WJ, et al. Histopathologic and immunohistochemical features of fatal influenza virus infection in children during the 2003–2004 season. Clin Infect Dis. 2006;43:132–40.
    1. Mamas MA, Fraser D, Neyses L. Cardiovascular manifestations associated with influenza virus infection. Int J Cardiol. 2008;130:304–9.
    1. Abe M, Higuchi T, Okada K, Kaizu K, Matsumoto K. Clinical study of influenza-associated rhabdomyolysis with acute renal failure. Clin Nephrol. 2006;66:166–70.
    1. Annerstedt M, Herlitz H, Molne J, Oldfors A, Westberg G. Rhabdomyolysis and acute renal failure associated with influenza virus type A. Scand J Urol Nephrol. 1999;33:260–4.
    1. Naderi AS, Palmer BF. Rhabdomyolysis and acute renal failure associated with influenza virus type B infection. Am J Med Sci. 2006;332:88–9.
    1. Maricich SM, Neul JL, Lotze TE, et al. Neurologic complications associated with influenza A in children during the 2003–2004 influenza season in Houston, Texas. Pediatrics. 2004;114:e626–33.
    1. Morishima T, Togashi T, Yokota S, et al. Encephalitis and encephalopathy associated with an influenza epidemic in Japan. Clin Infect Dis. 2002;35:512–7.
    1. Nagao T, Morishima T, Kimura H, et al. Prognostic factors in influenza-associated encephalopathy. Pediatr Infect Dis J. 2008;27:384–9.
    1. Newland JG, Laurich VM, Rosenquist AW, et al. Neurologic complications in children hospitalized with influenza: characteristics, incidence, and risk factors. J Pediatr. 2007;150:306–10.
    1. Steininger C, Popow-Kraupp T, Laferl H, et al. Acute encephalopathy associated with influenza A virus infection. Clin Infect Dis. 2003;36:567–74.
    1. Bhat N, Wright JG, Broder KR, et al. Influenza-associated deaths among children in the United States, 2003–2004. N Engl J Med. 2005;353:2559–67.
    1. Chang LY, Lee PI, Lin YJ, Chiu HH, Huang LM, Lee CY. Influenza B virus infection associated with shock in a two-month-old infant. J Formos Med Assoc. 1996;95:703–5.
    1. Conway EE, Jr, Haber RS, Gumprecht J, Singer LP. Toxic shock syndrome following influenza A in a child. Crit Care Med. 1991;19:123–5.
    1. MacDonald KL, Osterholm MT, Hedberg CW, et al. Toxic shock syndrome: a newly recognized complication of influenza and influenzalike illness. JAMA. 1987;257:1053–8.
    1. Sharkey R, Mulloy E, O'Neill G, Walker F, O'Neill S. Toxic shock syndrome following influenza A infection. Intensive Care Med. 1999;25:335–6.
    1. Tolan RW., Jr Toxic shock syndrome complicating influenza A in a child: case report and review. Clin Infect Dis. 1993;17:43–5.
    1. Brundage JF. Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness. Lancet Infect Dis. 2006;6:303–12.
    1. Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003–04 influenza season. Emerg Infect Dis. 2006;12:894–9.
    1. Peltola VT, McCullers JA. Respiratory viruses predisposing to bacterial infections: role of neuraminidase. Pediatr Infect Dis J. 2004;23((Suppl 1)):S87–97.
    1. Centers for Disease Control and Prevention. Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza—Louisiana and Georgia, December 2006–January 2007. MMWR Morb Mortal Wkly Rep. 2007;56:325–9.
    1. Finelli L, Fiore A, Dhara R, et al. Influenza-associated pediatric mortality in the United States: increase of Staphylococcus aureus coinfection. Pediatrics. 2008;122:805–11.
    1. Davis MM, Taubert K, Benin AL, et al. Influenza vaccination as secondary prevention for cardiovascular disease: a science advisory from the American Heart Association/American College of Cardiology. J Am Coll Cardiol. 2006;48:1498–502.
    1. Mamas MA, Nair S, Fraser D. Cardiac tamponade and heart failure as a presentation of influenza. Exp Clin Cardiol. 2007;12:214–6.
    1. Miller EK, Griffin MR, Edwards KM, et al. Influenza burden for children with asthma. Pediatrics. 2008;121:1–8.
    1. Varkey JB, Varkey B. Viral infections in patients with chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2008;14:89–94.
    1. Babcock HM, Merz LR, Fraser VJ. Is influenza an influenza-like illness? Clinical presentation of influenza in hospitalized patients. Infect Control Hosp Epidemiol. 2006;27:266–70.
    1. Govaert TM, Dinant GJ, Aretz K, Knottnerus JA. The predictive value of influenza symptomatology in elderly people. Fam Pract. 1998;15:16–22.
    1. Monmany J, Rabella N, Margall N, Domingo P, Gich I, Vazquez G. Unmasking influenza virus infection in patients attended to in the emergency department. Infection. 2004;32:89–97.
    1. Nicholson KG, Kent J, Hammersley V, Cancio E. Acute viral infections of upper respiratory tract in elderly people living in the community: comparative, prospective, population based study of disease burden. BMJ. 1997;315:1060–4.
    1. Walsh EE, Cox C, Falsey AR. Clinical features of influenza A virus infection in older hospitalized persons. J Am Geriatr Soc. 2002;50:1498–503.
    1. Carrat F, Leruez-Ville M, Tonnellier M, et al. A virologic survey of patients admitted to a critical care unit for acute cardiorespiratory failure. Intensive Care Med. 2006;32:156–9.
    1. Izurieta HS, Thompson WW, Kramarz P, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med. 2000;342:232–9.
    1. Keren R, Zaoutis TE, Bridges CB, et al. Neurological and neuromuscular disease as a risk factor for respiratory failure in children hospitalized with influenza infection. JAMA. 2005;294:2188–94.
    1. Louie JK, Schechter R, Honarmand S, et al. Severe pediatric influenza in California, 2003–2005: implications for immunization recommendations. Pediatrics. 2006;117:e610–8.
    1. Mullooly JP, Bridges CB, Thompson WW, et al. Influenza- and RSV-associated hospitalizations among adults. Vaccine. 2007;25:846–55.
    1. Neuzil KM, Mellen BG, Wright PF, Mitchel EF, Jr, Griffin MR. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med. 2000;342:225–31.
    1. Neuzil KM, Reed GW, Mitchel EF, Jr, Griffin MR. Influenza-associated morbidity and mortality in young and middle-aged women. JAMA. 1999;281:901–7.
    1. Neuzil KM, Reed GW, Mitchel EF, Simonsen L, Griffin MR. Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. Am J Epidemiol. 1998;148:1094–102.
    1. Neuzil KM, Wright PF, Mitchel EF, Jr, Griffin MR. The burden of influenza illness in children with asthma and other chronic medical conditions. J Pediatr. 2000;137:856–64.
    1. Neuzil KM, Zhu Y, Griffin MR, et al. Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. J Infect Dis. 2002;185:147–52.
    1. O'Brien MA, Uyeki TM, Shay DK, et al. Incidence of outpatient visits and hospitalizations related to influenza in infants andyoung children. Pediatrics. 2004;113:585–93.
    1. Schrag SJ, Shay DK, Gershman K, et al. Multistate surveillance for laboratory-confirmed, influenza-associated hospitalizations in children: 2003–2004. Pediatr Infect Dis J. 2006;25:395–400.
    1. Nichol KL, Treanor JJ. Vaccines for seasonal and pandemic influenza. J Infect Dis. 2006;194((Suppl 2)):S111–8.
    1. Horcajada JP, Pumarola T, Martinez JA, et al. A nosocomial outbreak of influenza during a period without influenza epidemic activity. Eur Respir J. 2003;21:303–7.
    1. Leekha S, Zitterkopf NL, Espy MJ, Smith TF, Thompson RL, Sampathkumar P. Duration of influenza A virus shedding in hospitalized patients and implications for infection control. Infect Control Hosp Epidemiol. 2007;28:1071–6.
    1. Sagrera X, Ginovart G, Raspall F, et al. Outbreaks of influenza A virus infection in neonatal intensive care units. Pediatr Infect Dis J. 2002;21:196–200.
    1. Salgado CD, Farr BM, Hall KK, Hayden FG. Influenza in the acute hospital setting. Lancet Infect Dis. 2002;2:145–55.
    1. Sartor C, Zandotti C, Romain F, et al. Disruption of services in an internal medicine unit due to a nosocomial influenza outbreak. Infect Control Hosp Epidemiol. 2002;23:615–9.
    1. Slinger R, Dennis P. Nosocomial influenza at a Canadian pediatric hospital from 1995 to 1999: opportunities for prevention. Infect Control Hosp Epidemiol. 2002;23:627–9.
    1. Camps M, Vilella A, Marcos MA, et al. Incidence of respiratory viruses among travelers with a febrile syndrome returning from tropical and subtropical areas. J Med Virol. 2008;80:711–5.
    1. Luna LK, Panning M, Grywna K, Pfefferle S, Drosten C. Spectrum of viruses and atypical bacteria in intercontinental air travelers with symptoms of acute respiratory infection. J Infect Dis. 2007;195:675–9.
    1. Miller JM, Tam TW, Maloney S, et al. Cruise ships: high-risk passengers and the global spread of new influenza viruses. Clin Infect Dis. 2000;31:433–8.
    1. Mutsch M, Tavernini M, Marx A, et al. Influenza virus infection in travelers to tropical and subtropical countries. Clin Infect Dis. 2005;40:1282–7.
    1. Ortiz JR, Wallis TR, Katz MA, et al. No evidence of avian influenza A (H5N1) among returning US travelers. Emerg Infect Dis. 2007;13:294–7.
    1. Uyeki TM, Zane SB, Bodnar UR, et al. Large summertime influenza A outbreak among tourists in Alaska and the Yukon Territory. Clin Infect Dis. 2003;36:1095–102.
    1. Frank AL, Taber LH, Wells CR, Wells JM, Glezen WP, Paredes A. Patterns of shedding of myxoviruses and paramyxoviruses in children. J Infect Dis. 1981;144:433–41.
    1. Sato M, Hosoya M, Kato K, Suzuki H. Viral shedding in children with influenza virus infections treated with neuraminidase inhibitors. Pediatr Infect Dis J. 2005;24:931–2.
    1. Klimov AI, Rocha E, Hayden FG, Shult PA, Roumillat LF, Cox NJ. Prolonged shedding of amantadine-resistant influenza A viruses by immunodeficient patients: detection by polymerase chain reaction–restriction analysis. J Infect Dis. 1995;172:1352–5.
    1. Weinstock DM, Gubareva LV, Zuccotti G. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N Engl J Med. 2003;348:867–8.
    1. Hota S, McGeer A. Antivirals and the control of influenza outbreaks. Clin Infect Dis. 2007;45:1362–8.
    1. Frayha H, Castriciano S, Mahony J, Chernesky M. Nasopharyngeal swabs and nasopharyngeal aspirates equally effective for the diagnosis of viral respiratory disease in hospitalized children. J Clin Microbiol. 1989;27:1387–9.
    1. Heikkinen T, Marttila J, Salmi AA, Ruuskanen O. Nasal swab versus nasopharyngeal aspirate for isolation of respiratory viruses. J Clin Microbiol. 2002;40:4337–9.
    1. Lambert SB, Whiley DM, O'Neill NT, et al. Comparing nose-throat swabs and nasopharyngeal aspirates collected from children with symptoms for respiratory virus identification using real-time polymerase chain reaction. Pediatrics. 2008;122:e615–20.
    1. Sung RY, Chan PK, Choi KC, et al. Comparative study of nasopharyngeal aspirate and nasal swab specimens for diagnosis of acute viral respiratory infection. J Clin Microbiol. 2008;46:3073–6.
    1. Uyeki TM. Influenza diagnosis and treatment in children: a review of studies on clinically useful tests and antiviral treatment for influenza. Pediatr Infect Dis J. 2003;22:164–77.
    1. Robinson JL, Lee BE, Kothapalli S, Craig WR, Fox JD. Use of throat swab or saliva specimens for detection of respiratory viruses in children. Clin Infect Dis. 2008;46:e61–4.
    1. Simpson JL, Moric I, Wark PA, Johnston SL, Gibson PG. Use of induced sputum for the diagnosis of influenza and infections in asthma: a comparison of diagnostic techniques. J Clin Virol. 2003;26:339–46.
    1. Kimball AM, Foy HM, Cooney MK, Allan ID, Matlock M, Plorde JJ. Isolation of respiratory syncytial and influenza viruses from the sputum of patients hospitalized with pneumonia. J Infect Dis. 1983;147:181–4.
    1. Agoritsas K, Mack K, Bonsu BK, Goodman D, Salamon D, Marcon MJ. Evaluation of the Quidel QuickVue test for detection of influenza A and B viruses in the pediatric emergency medicine setting by use of three specimen collection methods. J Clin Microbiol. 2006;44:2638–41.
    1. Dale SE, Mayer C, Mayer MC, Menegus MA. Analytical and clinical sensitivity of the 3M rapid detection influenza A+B assay. J Clin Microbiol. 2008;46:3804–7.
    1. Grijalva CG, Poehling KA, Edwards KM, et al. Accuracy and interpretation of rapid influenza tests in children. Pediatrics. 2007;119:e6–11.
    1. Hurt AC, Alexander R, Hibbert J, Deed N, Barr IG. Performance of six influenza rapid tests in detecting human influenza in clinical specimens. J Clin Virol. 2007;39:132–5.
    1. Rashid H, Shafi S, Haworth E, et al. Value of rapid testing for influenza among Hajj pilgrims. Travel Med Infect Dis. 2007;5:310–3.
    1. Uyeki TM, Prasad PP, Vukotich C, et al. Low rapid influenza diagnostic test sensitivity. Clin Infect Dis. (in press).
    1. McGeer AJ. Diagnostic testing or empirical therapy for patients hospitalized with suspected influenza: what to do? Clin Infect Dis. 2009;48((Suppl 1)):S14–9.
    1. Landry ML, Cohen S, Ferguson D. Real-time PCR compared to Binax NOW and cytospin-immunofluorescence for detection of influenza in hospitalized patients. J Clin Virol. 2008;43:148–51.
    1. Cruz AT, Cazacu AC, Greer JM, Demmler GJ. Rapid assays for the diagnosis of influenza A and B viruses in patients evaluated at a large tertiary care children's hospital during two consecutive winter seasons. J Clin Virol. 2008;41:143–7.
    1. Rahman M, Kieke BA, Vandermause MF, Mitchell PD, Greenlee RT, Belongia EA. Performance of Directigen flu A+B enzyme immunoassay and direct fluorescent assay for detection of influenza infection during the 2004–2005 season. Diagn Microbiol Infect Dis. 2007;58:413–8.
    1. Ali T, Scott N, Kallas W, et al. Detection of influenza antigen with rapid antibody-based tests after intranasal influenza vaccination (FluMist) Clin Infect Dis. 2004;38:760–2.
    1. Vesikari T, Karvonen A, Korhonen T, et al. A randomized, double-blind study of the safety, transmissibility^and phenotypic and genotypic stability of cold-adapted influenza virus vaccine, SLH. Pediatr Infect Dis J. 2006;25:590–5.
    1. Bright RA, Medina MJ, Xu X, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet. 2005;366:1175–81.
    1. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. Adamantane resistance among influenza A viruses isolated early during the 2005–2006 influenza season in the United States. JAMA. 2006;295:891–4.
    1. Deyde VM, Xu X, Bright RA, et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis. 2007;196:249–57.
    1. Kawai N, Ikematsu H, Iwaki N, et al. A comparison of the effectiveness of zanamivir and oseltamivir for the treatment of influenza A and B. J Infect. 2008;56:51–7.
    1. Sato M, Saito R, Sato I, et al. Effectiveness of oseltamivir treatment among children with influenza A or B virus infections during four successive winters in Niigata City, CZH, Japan. Tohoku J Exp Med. 2008;214:113–20.
    1. Monto AS, McKimm-Breschkin JL, Macken C, et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother. 2006;50:2395–402.
    1. Neuraminidase Inhibitor Susceptibility Network. Monitoring of neuraminidase inhibitor resistance among clinical influenza virus isolates in Japan during the 2003–2006 influenza seasons. Wkly Epidemiol Rec. 2007;82:149–50.
    1. Centers for Disease Control and Prevention. CDC issues interim recommendations for the use of influenza antiviral medications in the settingof oseltamivir resistance among circulating influenza A (H1N1) viruses, 2008–09 influenza season, 2008. [Accessed 28 January 2009.]; Available at: .
    1. Hauge SH, Dudman SG, Borgen K, Lackenby A, Hungnes O. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007–08. Emerg Infect Dis. 2009;15:155–62.
    1. Hayden F. Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis. 2009;48((Suppl 1)):S3–13.
    1. Besselaar TG, Dhamari N, Buys A, et al. Widespread oseltamivir resistance in influenza A viruses (H1N1), South Africa. Emerg Infect Dis. 2008;14:1809–10.
    1. Centers for Disease Control and Prevention. Update: influenza activity—United States, September 30, 2007–February 9, 2008. MMWR Morb Mortal Wkly Rep. 2008;57:179–83.
    1. Ciancio B, Fernandez de la Hoz K, Kreidl P, et al. Oseltamivir resistance in human seasonal influenza viruses (A/H1N1) in EU and EFTA countries: an update. Euro Surveill. 2008;13:8032.
    1. Lackenby A, Hungnes O, Dudman SG, et al. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill. 2008;13:8026.
    1. Lackenby A, Thompson CI, Democratis J. The potential impact of neuraminidase inhibitor resistant influenza. Curr Opin Infect Dis. 2008;21:626–38.
    1. Nicoll A, Ciancio B, Kramarz P. Observed oseltamivir resistance in seasonal influenza viruses in Europe interpretation and potential implications. Euro Surveill. 2008;13:8025.
    1. Sheu TG, Deyde VM, Okomo-Adhiambo M, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother. 2008;52:3284–92.
    1. Okamoto S, Kamiya I, Kishida K, Shimakawa T, Fukui T, Morimoto T. Experience with oseltamivir for infants younger than 1 year old in Japan. Pediatr Infect Dis J. 2005;24:575–6.
    1. Tamura D, Miura T, Kikuchi Y. Oseltamivir phosphate in infants under 1 year of age with influenza infection. Pediatr Int. 2005;47:484.
    1. Shalabi M, Abughali N, Abzug M, et al. for the NIAID Collaborative Antiviral Study Group (CASG) Safety of osetamivir vs. adamantane or rmiantadine in children under 1 year of age.. Program and abstracts of the 45th Annual Meeting of the Infectious Diseases Society of America; (San Diego).. Alexandria, VA: Infectious Diseases Society of America; 2007.
    1. Gilbert BE, Wilson SZ, Knight V, et al. Ribavirin small-particle aerosol treatment of infections caused by influenza virus strains A/Victoria/7/83 (H1N1) and B/Texas/1/84. Antimicrob Agents Chemother. 1985;27:309–13.
    1. Knight V, McClung HW, Wilson SZ, et al. Ribavirin small-particle aerosol treatment of influenza. Lancet. 1981;2:945–9.
    1. McClung HW, Knight V, Gilbert BE, Wilson SZ, Quarles JM, Divine GW. Ribavirin aerosol treatment of influenza B virus infection. JAMA. 1983;249:2671–4.
    1. Wilson SZ, Gilbert BE, Quarles JM, et al. Treatment of influenza A (H1N1) virus infection with ribavirin aerosol. Antimicrob Agents Chemother. 1984;26:200–3.
    1. Rodriguez WJ, Hall CB, Welliver R, et al. Efficacy and safety of aerosolized ribavirin in young children hospitalized with influenza: a double-blind, multicenter, placebo-controlled trial. J Pediatr. 1994;125:129–35.
    1. Stein DS, Creticos CM, Jackson GG, et al. Oral ribavirin treatment of influenza A and B. Antimicrob Agents Chemother. 1987;31:1285–7.
    1. Hayden FG, Sable CA, Connor JD, Lane J. Intravenous ribavirin by constant infusion for serious influenza and parainfluenzavirus infection. Antivir Ther. 1996;1:51–6.
    1. Ilyushina NA, Hay A, Yilmaz N, Boon AC, Webster RG, Govorkova EA. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob Agents Chemother. 2008;52:3889–97.
    1. Madren LK, Shipman C, Hayden FG. In vitro inhibitory effects of combinations of anti-influenza agents. Antivir Chem Chemother. 1995;6:109–13.
    1. Jefferson TO, Demicheli V, Di Pietrantonj C, Jones M, Rivetti D. Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database Syst Rev. 2006;3:CD001265.
    1. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med. 2003;163:1667–72.
    1. Nordstrom BL, Sung I, Suter P, Szneke P. Risk of pneumonia and other complications of influenza-like illness in patients treated with oseltamivir. Curr Med Res Opin. 2005;21:761–8.
    1. Lee N, Chan PK, Choi KW, et al. Factors associated with early hospital discharge of adult influenza patients. Antivir Ther. 2007;12:501–8.
    1. Jefferson T, Demicheli V, Rivetti D, Jones M, Di Pietrantonj C, Rivetti A. Antivirals for influenza in healthy adults: systematic review. Lancet. 2006;367:303–13.
    1. Monto AS, Webster A, Keene O. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. J Antimicrob Chemother. 1999;44((Suppl B)):23–9.
    1. Lalezari J, Campion K, Keene O, Silagy C. Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials. Arch Intern Med. 2001;161:212–7.
    1. Bowles SK, Lee W, Simor AE, et al. Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999–2000. J Am Geriatr Soc. 2002;50:608–16.
    1. Chemaly RF, Torres HA, Aguilera EA, et al. Neuraminidase inhibitors improve outcome of patients with leukemia and influenza: an observational study. Clin Infect Dis. 2007;44:964–7.
    1. Nichols WG. Combating infections in hematopoietic stem cell transplant recipients. Expert Rev Anti Infect Ther. 2003;1:57–73.
    1. Nichols WG. Management of infectious complications in the hematopoietic stem cell transplant recipient. J Intensive Care Med. 2003;18:295–312.
    1. Blumentals WA, Schulman KL. Impact of oseltamivir on the incidence of secondary complications of influenza in adolescent and adult patients: results from a retrospective population-based study. Curr Med Res Opin. 2007;23:2961–70.
    1. Orzeck EA, Shi N, Blumentals WA. Oseltamivir and the risk of influenza-related complications and hospitalizations in patients with diabetes. Clin Ther. 2007;29:2246–55.
    1. Cooper NJ, Sutton AJ, Abrams KR, Wailoo A, Turner D, Nicholson KG. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ. 2003;326:1235.
    1. Carrat F, Vergu E, Ferguson NM, et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol. 2008;167:775–85.
    1. Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA. 1999;282:1240–6.
    1. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA. 2000;283:1016–24.
    1. Aoki FY, Macleod MD, Paggiaro P, et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother. 2003;51:123–9.
    1. Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. GG167 Influenza Study Group. N Engl J Med. 1997;337:874–80.
    1. McGeer A, Green KA, Plevneshi A, et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis. 2007;45:1568–75.
    1. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J. 2001;20:127–33.
    1. Johnston SL, Ferrero F, Garcia ML, Dutkowski R. Oral oseltamivir improves pulmonary function and reduces exacerbation frequency for influenza-infected children with asthma. Pediatr Infect Dis J. 2005;24:225–32.
    1. Barr CE, Schulman K, Iacuzio D, Bradley JS. Effect of oseltamivir on the risk of pneumonia and use of health care services in children with clinically diagnosed influenza. Curr Med Res Opin. 2007;23:523–31.
    1. Hedrick JA, Barzilai A, Behre U, et al. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J. 2000;19:410–7.
    1. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Lancet. 1998;352:1877–81.
    1. Makela MJ, Pauksens K, Rostila T, et al. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. J Infect. 2000;40:42–8.
    1. Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections. J Infect Dis. 1999;180:254–61.
    1. Sugaya N, Tamura D, Yamazaki M, et al. Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children. Clin Infect Dis. 2008;47:339–45.
    1. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet. 2004;364:759–65.
    1. Stephenson I, Democratis J, Lackenby A, et al. Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. Clin Infect Dis. 2009 [Epub ahead of print]
    1. Baz M, Abed Y, McDonald J, Boivin G. Characterization ofmultidrugresistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin Infect Dis. 2006;43:1555–61.
    1. Ison MG, Gubareva LV, Atmar RL, Treanor J, Hayden FG. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis. 2006;193:760–4.
    1. Hatakeyama S, Sugaya N, Ito M, et al. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA. 2007;297:1435–42.
    1. van der Vries E, van den Berg B, Schutten M. Fatal oseltamivirresistant influenza virus infection. N Engl J Med. 2008;359:1074–6.
    1. Roche. Oseltamivir [package insert] Nutley, NJ: Roche; 2008. Available at: .
    1. US Food and Drug Administration. FDA Pediatric Advisory Committee meeting on adverse event reports, focusing on neuropsychiatric and behavioral events, for Tamiflu (oseltamivir) [FDA transcript] 2007
    1. Schnirring L. Japanese study finds no behavioral effects from Tamiflu. [Accessed 21 November 2008];2008 Available at: .
    1. McGeer AJ, Lee W, Loeb M, et al. Adverse effects of amantadine and oseltamivir used during respiratory outbreaks in a center for developmentally disabled adults. Infect Control Hosp Epidemiol. 2004;25:955–61.
    1. GSK. Philadelphia: GSK; 2008. Zanamivir [package insert] Available at: ttp://.
    1. Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis. 1999;180:254–61.
    1. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med. 2005;353:1363–73.
    1. Williamson JC, Pegram PS. Respiratory distress associated with zanamivir. N Engl J Med. 2000;342:661–2.
    1. Murphy KR, Elvindson A, Pauksens K, Stein WJ. Efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma or chronic obstructive pulmonary disease: a double-blind, randomised, placebo-controlled, multicentre study. Clin Drug Investig. 2000;20:337–49.
    1. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44((Suppl 2)):S27–72.
    1. Hayden FG, Pavia AT. Antiviral management of seasonal and pandemic influenza. J Infect Dis. 2006;194((Suppl 2)):S119–26.
    1. London: National Institute for Health and Clinical Excellence; 2008. Oseltamvir, amantadine (review) and zanamivir for the prophylaxis of influenza.
    1. Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG, Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med. 1989;321:1696–702.
    1. Hayden FG, Gubareva LV, Monto AS, et al. Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. N Engl J Med. 2000;343:1282–9.
    1. Monto AS, Pichichero ME, Blanckenberg SJ, et al. Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. J Infect Dis. 2002;186:1582–8.
    1. Hayden FG, Belshe R, Villanueva C, et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis. 2004;189:440–9.
    1. Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA. 2001;285:748–54.
    1. Rubin MS, Nivin B, Ackelsberg J. Effect of timing of amantadine chemoprophylaxis on severity of outbreaks of influenza A in adult long-term care facilities. Clin Infect Dis. 2008;47:47–52.
    1. Peters PH, Jr, Gravenstein S, Norwood P, et al. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc. 2001;49:1025–31.
    1. Monto AS, Rotthoff J, Teich E, et al. Detection and control of influenza outbreaks in well-vaccinated nursing home populations. Clin Infect Dis. 2004;39:459–64.
    1. Gravenstein S, Drinka P, Osterweil D, et al. Inhaled zanamivir versus rimantadine for the control of influenza in a highly vaccinated longterm care population. J Am Med Dir Assoc. 2005;6:359–66.
    1. Chemaly RF, Ghosh S, Bodey GP, et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore) 2006;85:278–87.
    1. Vu D, Peck AJ, Nichols WG, et al. Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study. Clin Infect Dis. 2007;45:187–93.
    1. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature. Ann Intern Med. 1995;123:518–27.
    1. Nichol KL, Margolis KL, Wouremna J, von Sternberg T. Effectiveness of influenza vaccine in the elderly. Gerontology. 1996;42:274–9.
    1. Tasker SA, Treanor JJ, Paxton WB, Wallace MR. Efficacy of influenza vaccination in HIV-infected persons: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1999;131:430–3.
    1. Yamanaka H, Teruya K, Tanaka M, et al. Efficacy and immunologic responses to influenza vaccine in HIV-1–infected patients. J Acquir Immune Defic Syndr. 2005;39:167–73.
    1. Kroon FP, van Dissel JT, de Jong JC, Zwinderman K, van Furth R. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine. 2000;18:3040–9.
    1. Smith PW, Bennett G, Bradley S, et al. SHEA/APIC guideline: infection prevention and control in the long-term care facility, July 2008. Infect Control Hosp Epidemiol. 2008;29:785–814.
    1. Bradley SF. Prevention of influenza in long-term-care facilities. LongTerm-Care Committee of the Society for Healthcare Epidemiology of America. Infect Control Hosp Epidemiol. 1999;20:629–37.
    1. Sneller VP, Izurieta H, Bridges CB, et al. Prevention and control of vaccine-preventable diseases in long-term care facilities. J Am Med Dir Assoc. 2000:S1–37.
    1. Drinka PJ, Krause P, Nest L, Goodman BM, Gravenstein S. Risk of acquiring influenza A in a nursing home from a culture-positive roommate. Infect Control Hosp Epidemiol. 2003;24:872–4.
    1. Bridges CB, Kuehnert MJ, Hall CB. Transmission of influenza: implications for control in health care settings. Clin Infect Dis. 2003;37:1094–101.
    1. Gomolin IH, Leib HB, Arden NH, Sherman FT. Control of influenza outbreaks in the nursing home: guidelines for diagnosis and management. J Am Geriatr Soc. 1995;43:71–4.
    1. Siegel J, Rhinehart E, Jackson M, Chiarello L the Healthcare Infection Control Practices Advisory Committee. 2007 Guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings. [Accessed 4 March 2009];2007 Available at: .
    1. Zadeh MM, Buxton Bridges C, Thompson WW, Arden NH, Fukuda K. Influenza outbreak detection and control measures in nursing homes in the United States. J Am Geriatr Soc. 2000;48:1310–5.
    1. Bridges CB, Harper S. The full-court press for influenza prevention in elderly persons. Clin Infect Dis. 2004;39:465–7.
    1. Drinka PJ, Gravenstein S, Krause P, et al. Non-influenza respiratory viruses may overlap and obscure influenza activity. J Am Geriatr Soc. 1999;47:1087–93.
    1. Ellis SE, Coffey CS, Mitchel EF, Jr, Dittus RS, Griffin MR. Influenza-and respiratory syncytial virus–associated morbidity and mortality in the nursing home population. J Am Geriatr Soc. 2003;51:761–7.
    1. Lee C, Loeb M, Phillips A, et al. Zanamivir use during transmission of amantadine-resistant influenza A in a nursing home. Infect Control Hosp Epidemiol. 2000;21:700–4.
    1. Parker R, Loewen N, Skowronski D. Experience with oseltamivir in the control of a nursing home influenza B outbreak. Can Commun Dis Rep. 2001;27:37–40.
    1. Schilling M, Povinelli L, Krause P, et al. Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine. 1998;16:1771–4.
    1. van der Sande MA, Ruijs WL, Meijer A, Cools HJ, van der Plas SM. Use of oseltamivir in Dutch nursing homes during the 2004–2005 influenza season. Vaccine. 2006;24:6664–9.
    1. Cohen NJ, Morita JY, Plate DK, et al. Control of an outbreak due to an adamantane-resistant strain of influenza A (H3N2) in a chronic care facility. Infection. 2008;36:458–62.
    1. Monto AS, Ohmit SE, Hornbuckle K, Pearce CL. Safety and efficacy of long-term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrob Agents Chemother. 1995;39:2224–8.
    1. Ong AK, Hayden FG, John F. Enders lecture 2006: antivirals for influenza. J Infect Dis. 2007;196:181–90.
    1. Whitley RJ, Monto AS. Prevention and treatment of influenza in high-risk groups: children, pregnant women, immunocompromised hosts, and nursing home residents. J Infect Dis. 2006;194((Suppl 2)):S133–8.
    1. Risebrough NA, Bowles SK, Simor AE, McGeer A, Oh PI. Economic evaluation of oseltamivir phosphate for postexposure prophylaxis of influenza in long-term care facilities. J Am Geriatr Soc. 2005;53:444–51.
    1. Carman WF, Elder AG, Wallace LA, et al. Effects of influenza vaccination of health-care workers on mortality of elderly people in longterm care: a randomised controlled trial. Lancet. 2000;355:93–7.
    1. Potter J, Stott DJ, Roberts MA, et al. Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients. J Infect Dis. 1997;175:1–6.
    1. Pachucki CT, Pappas SA, Fuller GF, Krause SL, Lentino JR, Schaaff DM. Influenza A among hospital personnel and patients: implications for recognition, prevention, and control. Arch Intern Med. 1989;149:77–80.
    1. Drinka PJ, Gravenstein S, Schilling M, Krause P, Miller BA, Shult P. Duration of antiviral prophylaxis during nursing home outbreaks of influenza A: a comparison of 2 protocols. Arch Intern Med. 1998;158:2155–9.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere